What you should know:
– Syapse, a real-world evidence company that reports cancer care, announced that it will expand its partnership with Pfizer to generate real-world evidence on breast cancer.
– This is the third phase of the collaboration, which was first announced in 2019 and renewed in 2021.
Generate real-world evidence on breast cancer
As part of the next phase of the collaboration, Syapse will provide knowledge and services to Pfizer, using the Syapse Learning Health Network (LHN) to integrate, standardize, unidentify, and manage data. The knowledge gained from this collaboration will help grow the breast cancer data cohort and provide Pfizer with detailed patient-level information. Together, the two companies will continue to generate an unparalleled understanding of the experience of cancer patients and develop a higher level of care through real-world evidence.
– Syapse and Pfizer have co-authored two studies using LHN data. The first study, entitled “Real-world treatment patterns and clinical efficacy of palbociclib plus an aromatase inhibitor as a first-line therapy in advanced / metastatic breast cancer: Syapse Learning Network Health Analysis”Was presented at the 38th Annual Breast Cancer Conference in Miami. The second study, entitled “BRCA1 / 2 germline mutation tests on 2-negative human epidermal growth factor (HER2–) receptor Advanced breast cancer (ABC): a real-world study on the Syapse Learning Health Network (LHN)”Was presented at the 2021 San Antonio Breast Cancer Symposium.